Stryker Co. (SYK) Shares Bought by Xact Kapitalforvaltning AB
Xact Kapitalforvaltning AB grew its stake in shares of Stryker Co. (NYSE:SYK) by 7.3% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 57,539 shares of the medical technology company’s stock after acquiring an additional 3,912 shares during the period. Xact Kapitalforvaltning AB’s holdings in Stryker were worth $8,909,000 at the end of the most recent quarter.
Several other institutional investors also recently bought and sold shares of SYK. Amundi Pioneer Asset Management Inc. bought a new position in Stryker in the fourth quarter worth approximately $49,056,000. Elkfork Partners LLC bought a new position in Stryker in the fourth quarter worth approximately $49,005,000. Lazard Asset Management LLC raised its stake in Stryker by 15.5% in the fourth quarter. Lazard Asset Management LLC now owns 2,208,379 shares of the medical technology company’s stock worth $341,945,000 after buying an additional 296,550 shares in the last quarter. William Blair Investment Management LLC bought a new position in Stryker in the fourth quarter worth approximately $32,421,000. Finally, Janus Henderson Group PLC raised its stake in Stryker by 19.2% in the third quarter. Janus Henderson Group PLC now owns 1,214,733 shares of the medical technology company’s stock worth $172,517,000 after buying an additional 195,479 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently commented on SYK shares. Robert W. Baird raised shares of Stryker from a “neutral” rating to an “outperform” rating in a research note on Friday, November 24th. ValuEngine downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Needham & Company LLC reissued a “hold” rating on shares of Stryker in a research note on Thursday, December 7th. BMO Capital Markets raised shares of Stryker to a “market perform” rating and set a $163.00 price objective for the company in a research note on Tuesday, December 12th. Finally, JPMorgan Chase & Co. raised shares of Stryker from a “neutral” rating to an “overweight” rating in a research note on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and sixteen have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $164.76.
Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.95 by $0.01. The business had revenue of $3.47 billion for the quarter, compared to the consensus estimate of $3.42 billion. Stryker had a return on equity of 24.56% and a net margin of 8.20%. The business’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.78 earnings per share. equities research analysts anticipate that Stryker Co. will post 7.12 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date is Wednesday, March 28th. Stryker’s dividend payout ratio (DPR) is presently 70.15%.
In other news, VP William E. Berry, Jr. sold 1,306 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $164.42, for a total transaction of $214,732.52. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider David Floyd sold 55,119 shares of the business’s stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $166.58, for a total transaction of $9,181,723.02. The disclosure for this sale can be found here. Insiders have sold 98,730 shares of company stock worth $16,360,442 over the last three months. Corporate insiders own 7.40% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Stryker Co. (SYK) Shares Bought by Xact Kapitalforvaltning AB” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/stryker-co-syk-shares-bought-by-xact-kapitalforvaltning-ab/1960856.html.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.